Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Operating Expenses (2020 - 2026)

Edgewise Therapeutics has reported Operating Expenses over the past 7 years, most recently at $54.1 million for Q1 2026.

  • Quarterly results put Operating Expenses at $54.1 million for Q1 2026, up 17.75% from a year ago — trailing twelve months through Mar 2026 was $199.6 million (up 17.36% YoY), and the annual figure for FY2025 was $191.4 million, up 20.51%.
  • Operating Expenses reached $54.1 million in Q1 2026 per EWTX's latest filing, down from $56.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $56.0 million in Q4 2025 and bottomed at $14.8 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $34.8 million (2024), compared with a mean of $34.7 million.
  • The largest annual shift saw Operating Expenses surged 116.22% in 2022 before it rose 11.82% in 2025.
  • Over 5 years, Operating Expenses stood at $22.1 million in 2022, then soared by 53.37% to $33.9 million in 2023, then soared by 34.49% to $45.5 million in 2024, then increased by 22.92% to $56.0 million in 2025, then fell by 3.33% to $54.1 million in 2026.
  • Business Quant data shows Operating Expenses for EWTX at $54.1 million in Q1 2026, $56.0 million in Q4 2025, and $46.9 million in Q3 2025.